File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Outcome of hematopoietic stem cell transplantation In refractory/relapsed infant leukemia

TitleOutcome of hematopoietic stem cell transplantation In refractory/relapsed infant leukemia
Authors
KeywordsMedical sciences
Oncology medical sciences
Pediatrics
Issue Date2013
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1545-5017/
Citation
The 45th Congress of the International Society of Paediatric Oncology (SIOP 2013), Hong Kong, China, 25-28 September 2013. In Pediatric Blood & Cancer, 2013, v. 60 S3, p. 73, abstract no. P-0078 How to Cite?
AbstractPURPOSE/OBJECTIVE: Refractory/relapsed infant leukemia has an extremely poor prognosis. Whether hematopoietic stem cell transplantation (HSCT) can improve their outcome remains controversial. We reviewed our experience of HSCT on this group of patients. MATERIALS AND METHODS: This is a retrospective chart review on our HSCT patients’ cohort from Jan 1, 1995 to Dec 31, 2007. The indexed cases were identified from our HSCT electronic database from 1992 to 2007. RESULTS: Among >200 HSCT performed within this period, 8 patients with refractory/relapsed infant leukemia who underwent allogeneic HSCT were identified. Four patients had acute myeloid leukemia (AML); 2 had acute lymphoblastic leukemia (ALL); 1had juvenile myelomonocytic leukemia (JMML); and 1 had mixed lineage leukemia. Four patients had an initial white blood cell count >50_109/L, and 2 patients had cytogenetically detectable MLL rearrangement. For donor sources at first transplant, they were unrelated cord blood (n ? 1), unrelated bone marrow (BM, n ? 1) or related BM/peripheral blood stem cells (n ? 4). Three received busulphan/cyclophosphamide (AML) and one with busulphan/cyclophosphamide/melphalan (JMML) as conditioning and the other 4 had fludarabine based regimen with low dose irradiation. Seven patients achieved neutrophil engraftment at a median of 17 days (range: 13-22 days). Four patients relapsed after HSCT and 2 of them had upfront related HSCT. Despite second HSCT done in 2/4, all 4 of them died. Six patients experienced Grade III-IV acute graft versus host disease, and 5 (including the 2 with second transplant) developed various degree of hepatic venous-occlusive disease (VOD). Three patients (1ALL, 1AML & 1JMML) survived at 3, 8.8, and 13.8 years. The overall survival at 3 years was 37.5 +/- 17.1%. CONCLUSIONS: Despite having very poor prognosis, selected infants with refractory/relapsed leukemia could still be salvaged by allogeneic HSCT. We noted a high VOD and GvHD in our cohort so appropriate conditioning regimens should be adopted in the future.
DescriptionThis journal suppl. entitled: Supplement: SIOP Abstratcs: 45th Congress of the International Society of Paediatric Oncology (SIOP) ... 2013
Poster Presentation in Poster Session - Myeloid leukemias: abstract no. P-0078
Persistent Identifierhttp://hdl.handle.net/10722/193635
ISSN
2015 Impact Factor: 2.634
2015 SCImago Journal Rankings: 1.505

 

DC FieldValueLanguage
dc.contributor.authorXiong, Hen_US
dc.contributor.authorHa, SYen_US
dc.contributor.authorChiang, Aen_US
dc.contributor.authorCheuk, DKLen_US
dc.contributor.authorLi, Hen_US
dc.contributor.authorChan, Gen_US
dc.date.accessioned2014-01-20T05:12:14Z-
dc.date.available2014-01-20T05:12:14Z-
dc.date.issued2013en_US
dc.identifier.citationThe 45th Congress of the International Society of Paediatric Oncology (SIOP 2013), Hong Kong, China, 25-28 September 2013. In Pediatric Blood & Cancer, 2013, v. 60 S3, p. 73, abstract no. P-0078en_US
dc.identifier.issn1545-5009-
dc.identifier.urihttp://hdl.handle.net/10722/193635-
dc.descriptionThis journal suppl. entitled: Supplement: SIOP Abstratcs: 45th Congress of the International Society of Paediatric Oncology (SIOP) ... 2013-
dc.descriptionPoster Presentation in Poster Session - Myeloid leukemias: abstract no. P-0078-
dc.description.abstractPURPOSE/OBJECTIVE: Refractory/relapsed infant leukemia has an extremely poor prognosis. Whether hematopoietic stem cell transplantation (HSCT) can improve their outcome remains controversial. We reviewed our experience of HSCT on this group of patients. MATERIALS AND METHODS: This is a retrospective chart review on our HSCT patients’ cohort from Jan 1, 1995 to Dec 31, 2007. The indexed cases were identified from our HSCT electronic database from 1992 to 2007. RESULTS: Among >200 HSCT performed within this period, 8 patients with refractory/relapsed infant leukemia who underwent allogeneic HSCT were identified. Four patients had acute myeloid leukemia (AML); 2 had acute lymphoblastic leukemia (ALL); 1had juvenile myelomonocytic leukemia (JMML); and 1 had mixed lineage leukemia. Four patients had an initial white blood cell count >50_109/L, and 2 patients had cytogenetically detectable MLL rearrangement. For donor sources at first transplant, they were unrelated cord blood (n ? 1), unrelated bone marrow (BM, n ? 1) or related BM/peripheral blood stem cells (n ? 4). Three received busulphan/cyclophosphamide (AML) and one with busulphan/cyclophosphamide/melphalan (JMML) as conditioning and the other 4 had fludarabine based regimen with low dose irradiation. Seven patients achieved neutrophil engraftment at a median of 17 days (range: 13-22 days). Four patients relapsed after HSCT and 2 of them had upfront related HSCT. Despite second HSCT done in 2/4, all 4 of them died. Six patients experienced Grade III-IV acute graft versus host disease, and 5 (including the 2 with second transplant) developed various degree of hepatic venous-occlusive disease (VOD). Three patients (1ALL, 1AML & 1JMML) survived at 3, 8.8, and 13.8 years. The overall survival at 3 years was 37.5 +/- 17.1%. CONCLUSIONS: Despite having very poor prognosis, selected infants with refractory/relapsed leukemia could still be salvaged by allogeneic HSCT. We noted a high VOD and GvHD in our cohort so appropriate conditioning regimens should be adopted in the future.-
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1545-5017/-
dc.relation.ispartofPediatric Blood & Canceren_US
dc.rightsPediatric Blood & Cancer. Copyright © John Wiley & Sons, Inc.-
dc.subjectMedical sciences-
dc.subjectOncology medical sciences-
dc.subjectPediatrics-
dc.titleOutcome of hematopoietic stem cell transplantation In refractory/relapsed infant leukemiaen_US
dc.typeConference_Paperen_US
dc.identifier.emailHa, SY: syha@hku.hken_US
dc.identifier.emailChiang, A: chiangak@hku.hken_US
dc.identifier.emailCheuk, DKL: klcheuk@hkucc.hku.hken_US
dc.identifier.emailChan, G: gcfchan@hku.hken_US
dc.identifier.authorityChiang, A=rp00403en_US
dc.identifier.authorityChan, G=rp00431en_US
dc.identifier.doi10.1002/pbc.24719-
dc.identifier.hkuros227213en_US
dc.identifier.volume60-
dc.identifier.issueS3-
dc.identifier.spage73-
dc.identifier.epage73-
dc.publisher.placeUnited States-
dc.customcontrol.immutablesml 140710 - abstract embargo till 150901-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats